Screener
Summit Therapeutics SMMT Interest Expense
Discontinued — last reported Q4 '25
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Summit Therapeutics’s 10-K, filed February 23, 2026.
- Filed
- Feb 23, 2026, 4:10 PM EST
- Fiscal year
- FY2025
- Accession
- 0001599298-26-000015
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| General and administrative | 556,750 | 60,214 | 29,264 |
| Total operating expenses | 1,094,424 | 225,998 | 609,650 |
| Other income, net | 14,838 | 13,369 | 11,183 |
| Interest expense | — | (8,686) | (16,461) |
| Net loss | $(1,079,586) | $(221,315) | $(614,928) |
| Net loss per share: | |||
| Basic and diluted | $(1.44) | $(0.31) | $(0.99) |
| Weighted average common shares outstanding: |
Item 16. Report Summary
FAQ
- What is Summit Therapeutics's interest expense?
- Summit Therapeutics (SMMT) reported interest expense of $0 in Q4 2025.
- How has Summit Therapeutics's interest expense changed year-over-year?
- Summit Therapeutics's interest expense decreased by 100.0% year-over-year, from $9K to $0.
- What is the long-term trend for Summit Therapeutics's interest expense?
- Over 2 years (2022 to 2025), Summit Therapeutics's interest expense has grown at a -100.0% compound annual growth rate (CAGR), from $4.4M to $0.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Summit Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude